Skip to Content

How is Inflectra different from Remicade?

Answers (1)

Official Answer by Drugs.com 5 May 2016

Inflectra (infliximab-dyyb) by Celltrion is the second U.S. biosimilar approved by the FDA. Inflectra is classified as a tumor necrosis factor (TNF) blocker and is biosimilar to Janssen’s Remicade (infliximab), originally approved in 1998.

A biosimilar must have no clinically meaningful safety or effectiveness differences from the reference product, but it is not considered identical like a generic product.

Inflectra can be prescribed for the same uses as Remicade, including rheumatoid arthritis, Crohn’s disease, ankylosing spondylitis (spine arthritis), ulcerative colitis, psoriatic arthritis, and plaque psoriasis.

Votes: +1
Drugs.com free discount card

Further Information

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Frequently Asked Questions

How is Lartruvo administered?

Posted 2 days 23 hours ago 1 answerFAQ by Drugs.com

What are the clinical benefits of Exondys 51?

Posted 2 days 23 hours ago 1 answerFAQ by Drugs.com

How does Yosprala work?

Posted 2 days 23 hours ago 1 answerFAQ by Drugs.com

How is Cuvitru administered?

Posted 2 days 23 hours ago 1 answerFAQ by Drugs.com

How is Troxyca ER formulated to be abuse deterrent?

Posted 2 days 22 hours ago 1 answerFAQ by Drugs.com